Distal pancreatectomy in cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: Identifying risk and improving patient selection.


Journal

American journal of surgery
ISSN: 1879-1883
Titre abrégé: Am J Surg
Pays: United States
ID NLM: 0370473

Informations de publication

Date de publication:
11 2020
Historique:
received: 15 02 2020
revised: 22 04 2020
accepted: 25 06 2020
pubmed: 14 7 2020
medline: 5 1 2021
entrez: 14 7 2020
Statut: ppublish

Résumé

Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has become a principal tool in the management of peritoneal carcinomatosis (PC), but inclusion of pancreatic resection to obtain optimal debulking remains controversial. We performed a retrospective review of 419 patients with PC who underwent CRS/HIPEC. The patients were divided into two cohorts, those with distal pancreatectomy (DP) and those without (NP), and morbidity and survival outcomes were compared. The DP cohort (n = 37) and the NP cohort (n = 371) had similar clinicopathologic characteristics (age, p = 0.596; gender, p = 0.328; ASA, p = 0.072). Operative time, number of organs resected, and EBL were greater in the DP cohort (<0.0001). A complete cytoreduction was achieved in 90% of the NP cohort versus 69% of the DP cohort (p = 0.0004). Major perioperative morbidity was more common in those with pancreatic resection (41% vs 19%, p = 0.002). However, there was no significant difference in 90-day mortality or overall survival. Achieving complete cytoreduction is critical to improving long term outcomes for patients with PC. Although pancreatic resections are associated with higher morbidity, short-term survival is not impacted adversely. Pancreatic involvement should not be a strict exclusion criterion for CRS/HIPEC, but patients need to be selected carefully, with close attention to disease burden prior to proceeding.

Sections du résumé

BACKGROUND
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) has become a principal tool in the management of peritoneal carcinomatosis (PC), but inclusion of pancreatic resection to obtain optimal debulking remains controversial.
METHODS
We performed a retrospective review of 419 patients with PC who underwent CRS/HIPEC. The patients were divided into two cohorts, those with distal pancreatectomy (DP) and those without (NP), and morbidity and survival outcomes were compared.
RESULTS
The DP cohort (n = 37) and the NP cohort (n = 371) had similar clinicopathologic characteristics (age, p = 0.596; gender, p = 0.328; ASA, p = 0.072). Operative time, number of organs resected, and EBL were greater in the DP cohort (<0.0001). A complete cytoreduction was achieved in 90% of the NP cohort versus 69% of the DP cohort (p = 0.0004). Major perioperative morbidity was more common in those with pancreatic resection (41% vs 19%, p = 0.002). However, there was no significant difference in 90-day mortality or overall survival.
CONCLUSION
Achieving complete cytoreduction is critical to improving long term outcomes for patients with PC. Although pancreatic resections are associated with higher morbidity, short-term survival is not impacted adversely. Pancreatic involvement should not be a strict exclusion criterion for CRS/HIPEC, but patients need to be selected carefully, with close attention to disease burden prior to proceeding.

Identifiants

pubmed: 32654767
pii: S0002-9610(20)30400-1
doi: 10.1016/j.amjsurg.2020.06.045
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1235-1241

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Brianne J Sullivan (BJ)

Division of Surgical Oncology, Mount Sinai St. Luke's Roosevelt, USA. Electronic address: brianne.sullivan@mountsinai.org.

Natasha L Leigh (NL)

Division of Surgical Oncology, Mount Sinai St. Luke's Roosevelt, USA.

Eliahu Y Bekhor (EY)

Division of Surgical Oncology, Mount Sinai St. Luke's Roosevelt, USA.

Matthew Carpiniello (M)

Division of Surgical Oncology, Mount Sinai St. Luke's Roosevelt, USA.

Daniel Solomon (D)

Division of Surgical Oncology, Mount Sinai St. Luke's Roosevelt, USA.

Deepa R Magge (DR)

Division of Surgical Oncology, Mount Sinai St. Luke's Roosevelt, USA.

Umut Sarpel (U)

Division of Surgical Oncology, Mount Sinai St. Luke's Roosevelt, USA.

Benjamin J Golas (BJ)

Division of Surgical Oncology, Mount Sinai St. Luke's Roosevelt, USA.

Daniel M Labow (DM)

Division of Surgical Oncology, Mount Sinai St. Luke's Roosevelt, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH